- $12.22m
- $38.24m
- $1.02m
U.S. STOCKS ON THE MOVE-Tesla, TheStreet, Pluristem, Aveo Pharma, Pulmatrix
Pluristem: At record low on plans for public and direct offerings
Brief: Pluristem Therapeutics Announces Proposed Offering Of Common Stock, Warrants
Brief: Pluristem Therapeutics - Erez Egozi Will Cease To Be CFO
Brief: Pluristem Therapeutics Gets Approval To Enroll Final Cohort In Phase I Hematological Study Of PLX-R18
Brief: Pluristem Enters Into Collaboration With Nasa To Study PLX Therapeutic Benefits In Space Missions
Brief: Pluristem To Collaborate With Israeli Ministry Of Defense In The Treatment Of Burn Injuries
Brief: Pluristem Reports Successful Case Study In Treatment Of Buerger's Disease Patient
Brief: Pluristem Updates On Meeting With FDA On Development Plan For Acute Radiation Syndrome
Brief: Pluristem Therapeutics Enters Into Cell Thawing Device License Agreement With Chart Industries, Inc.
Brief: Pluristem Therapeutics Presents Data From First Cohort In Ongoing Phase I Hematological Study
Brief: Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results
Brief: Pluristem Therapeutics - U.S. FDA Approves Cost Recovery For PLX-PAD
Brief: Pluristem Reports Fiscal 2018 Fourth Quarter Results And Provides Corporate Update
Reuters Insider - U.S. Morning Call: Wall Street to open higher a day after new tariffs; Instagram; Consumer Confidence
Brief: Pluristem Therapeutics Announces FDA Orphan Drug Designation For PLX Cell Therapy
Pluristem: Gets FDA's orphan status for cell therapy in additional indications
Brief: Pluristem Initiates Two Pivotal Phase III Studies In Israel
Brief: Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific